Compare PSQH & CVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PSQH | CVM |
|---|---|---|
| Founded | 2021 | 1983 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Advertising | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.3M | 30.1M |
| IPO Year | 2021 | 1996 |
| Metric | PSQH | CVM |
|---|---|---|
| Price | $6.34 | $1.61 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 534.5K | 198.7K |
| Earning Date | 05-07-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 55.00 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $5,685,987.00 | $264,033.00 |
| Revenue This Year | $80.20 | N/A |
| Revenue Next Year | $34.74 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 1096.61 | 65.45 |
| 52 Week Low | $0.36 | $0.89 |
| 52 Week High | $6.94 | $12.68 |
| Indicator | PSQH | CVM |
|---|---|---|
| Relative Strength Index (RSI) | 74.78 | 56.85 |
| Support Level | $0.61 | $0.98 |
| Resistance Level | N/A | $1.68 |
| Average True Range (ATR) | 0.64 | 0.12 |
| MACD | 0.19 | -0.01 |
| Stochastic Oscillator | 94.85 | 54.08 |
PSQ Holdings Inc operates the website and mobile application named as PublicSq. It is an app and website that connects freedom-loving Americans to high-quality businesses that share values, both online and in local communities. It has three reportable segments comprised of Marketplace; which includes a marketplace platform to access consumers that are drawn to patriotic values and the revenue is generated in the form of advertising and eCommerce transactions, and Brands segment in which through its wholly-owned brand, the company generates revenue from online sales of diapers and wipes and third financial technology which assists consumers, lenders, and retailers in offering point-of-sale financing products.
CEL-SCI Corp is a late clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body's natural defense system. The company is focused on the development of the following product candidates and technologies: 1) Multikine, an investigational Phase 3 immunotherapy under development for the potential treatment of certain head and neck cancers; 2) LEAPS (Ligand Epitope Antigen Presentation System) technology, for the potential treatment of rheumatoid arthritis.